Capricor Therapeutics stock climbed 9.2% in pre-open trading to $9.14 after B.Riley shifted its view on the company from Neutral to Buy and raised its price target from $5 to $21. The firm framed the upgrade around what it described as an asymmetric opportunity into the November 22, 2026 PDUFA date for deramiocel, Capricor's investigational cell therapy for Duchenne muscular dystrophy.
B.Riley also identified the World Muscle Society conference on October 3, 2026 as a possible near-term re-rating event, noting the potential impact of open-label extension data presented there. That sequence - near-term data visibility followed by a definitive regulatory decision - is central to the analyst's revised recommendation.
The significance of B.Riley's move is amplified by the firm's previous posture. Until this upgrade, B.Riley had been among the most cautious on Wall Street toward CAPR, maintaining a Neutral rating and a $5 target while other firms had grown constructive. Cantor Fitzgerald had earlier upgraded Capricor to Overweight with a $28 target, Piper Sandler had moved to Overweight with a $25 target, and Oppenheimer initiated coverage with an Outperform rating and a $54 target. Those changes followed the FDA's acceptance of a major amendment to Capricor's biologics license application and the resulting extension of the PDUFA date to November 22.
With B.Riley abandoning its more conservative stance, a notable source of caution has been removed from the market's view, aligning more institutional analysts behind the deramiocel narrative. That consolidation of analyst sentiment appears to be driving the stock's gain today, rather than any broad market momentum.
Indeed, the wider market offered no support for risk assets in pre-market trading: the Nasdaq Composite was down 1.6%, the S&P 500 was off 0.6%, and the Dow Jones Industrial Average was lower by 0.4%. CAPR's near 10% rise against this backdrop underscores the company-specific nature of the move.
The share price has been volatile over the past year, with a 52-week range between $2.96 and $40.37, reflecting investor reaction to developments tied to deramiocel's regulatory pathway.
Clear summary
Capricor's stock jumped after B.Riley upgraded the shares to Buy and raised its price target to $21, citing an attractive asymmetry into the November 22, 2026 PDUFA date for deramiocel and calling out the October 3, 2026 World Muscle Society conference as a possible data-driven re-rating catalyst. This upgrade reduces a previously cautious voice on the stock and comes amid a broader set of bullish analyst views that followed FDA acceptance of a major BLA amendment.
Key points
- B.Riley upgraded CAPR from Neutral to Buy and lifted its price target from $5 to $21, highlighting the November 22, 2026 PDUFA date as the primary event underpinning its view.
- The World Muscle Society conference on October 3, 2026 is flagged as a potential near-term catalyst if open-label extension data prompt market reassessment.
- Other analysts had already adopted bullish stances after the FDA accepted a major amendment and extended the PDUFA date - Cantor Fitzgerald (Overweight, $28), Piper Sandler (Overweight, $25), and Oppenheimer (Outperform, $54) - and B.Riley's shift narrows prior dissent on the street.
Risks and uncertainties
- Regulatory outcome risk - the November 22, 2026 PDUFA decision on deramiocel is a single, binary event that could materially alter the company's outlook and investor sentiment.
- Data-event dependency - market expectations are tied to potential open-label extension data at the October 3, 2026 World Muscle Society conference; the actual content and market interpretation of that data create uncertainty.
- Volatility and concentration risk - CAPR's wide 52-week price range signals heightened sensitivity to program updates and analyst commentary, which can translate into rapid share-price swings.
Investor focus on Capricor is likely to remain elevated as the market moves toward the October conference and the November PDUFA date, particularly now that an earlier, outspoken skeptic has aligned with the broader positive analyst narrative.